Li Dengzhe, Li Xinqiang, Wen Bo, Li Boling, Wang Yan, Zong Yuan, Lyu Jun
Department of Intensive Care Unit, Shaanxi provincial people's hospital, Xi'an, China.
Department of Clinical Research, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251321314. doi: 10.1177/10760296251321314.
Markedly elevated serum ferritin serves as a laboratory marker of macrophage activation syndrome and is associated with increased mortality in sepsis, where hyperinflammation, coagulopathy, and immune dysregulation interplay. Although laboratory studies suggest a relationship between hyperferritinemia and coagulopathy in sepsis, clinical evidence remains limited. This study aims to assess mortality risk and the interplay between hyperferritinemia (ferritin ≥ 500 ng/mL) and thrombocytopenia in two sequential cohorts of adult patients with sepsis.
Patients with sepsis (≥18 years old) admitted to adult ICUs at Beth Israel Deaconess Medical Center between 2001 and 2008, and 2008 to 2019, with at least one ferritin value recorded within a 48-h window preceding or following the initial ICU admission.
Among 2339 eligible patients with hyperferritinemic sepsis, 921(39.4%) were categorized into the high ferritin (HF) group (ferritin ≥ 500 ng/mL). Multivariate logistic regression analysis revealed a significant association between the HF group and increased in-hospital mortality (p < .01). Survival analysis revealed significantly lower survival probabilities at 28 and 90 days in the HF group compared to the low ferritin group. The interaction between the HF group and thrombocytopenia revealed a statistically significant association with in-hospital mortality. Furthermore, causal mediation analysis showed that platelet count mediated 12.6% (95% CI: 0.063-0.27; p < .001) of the effect of elevated ferritin levels on in-hospital mortality.
Hyperferritinemia is associated with an increased mortality risk in adult septic patients. Thrombocytopenia not only interacts with hyperferritinemia but also serves as a mediating factor in its impact on mortality.
血清铁蛋白显著升高是巨噬细胞活化综合征的实验室标志物,且与脓毒症死亡率增加相关,脓毒症时存在过度炎症反应、凝血病和免疫失调的相互作用。虽然实验室研究提示脓毒症时高铁蛋白血症与凝血病之间存在关联,但临床证据仍然有限。本研究旨在评估成年脓毒症患者两个连续队列中,高铁蛋白血症(铁蛋白≥500 ng/mL)与血小板减少之间的相互作用及死亡风险。
2001年至2008年以及2008年至2019年期间入住贝斯以色列女执事医疗中心成人重症监护病房的脓毒症患者(≥18岁),在初次入住重症监护病房之前或之后的48小时内至少记录了一次铁蛋白值。
在2339例符合条件的高铁蛋白血症脓毒症患者中,921例(39.4%)被归类为高铁蛋白(HF)组(铁蛋白≥500 ng/mL)。多因素逻辑回归分析显示HF组与住院死亡率增加之间存在显著关联(p<0.01)。生存分析显示,与低铁蛋白组相比,HF组在28天和90天时的生存概率显著降低。HF组与血小板减少之间的相互作用显示与住院死亡率存在统计学显著关联。此外,因果中介分析表明,血小板计数介导了铁蛋白水平升高对住院死亡率影响的12.6%(95%CI:0.063-0.27;p<0.001)。
高铁蛋白血症与成年脓毒症患者死亡风险增加相关。血小板减少不仅与高铁蛋白血症相互作用,而且在其对死亡率的影响中起中介作用。